Measurement of growth hormone, insulin-like growth factor I and their binding proteins: The clinical aspects

Clinica Chimica Acta

Volumn 313, Issue 1-2, 2001, Pages 119-123

  Leung, Kin Chuen ^a   Ho, Ken K Y ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Acid labile subunit; Acromegaly; Growth hormone; Growth hormone deficiency; Insulin like growth factor

Indexed keywords

BIOCHEMICAL MARKER; GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; GROWTH HORMONE RECEPTOR; PROTEIN SUBUNIT; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; BLOOD LEVEL; CONFERENCE PAPER; DIAGNOSTIC TEST; GROWTH HORMONE DEFICIENCY; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; INSULIN TOLERANCE TEST; PRIORITY JOURNAL;

ADULT; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I;

EID: 0034748183     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00662-3     Document Type: Conference Paper

References (43)

1. Sexual dimorphism in the control of growth hormone secretion
2. The growth hormone receptor
3. Mode of action of pituitary growth hormone on target cells
4. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice
5. Normal growth and development in the absence of hepatic insulin-like growth factor I
6. Growth hormone-binding proteins
7. The serum growth hormone binding protein: Pregnant with possibilities
8. Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions
9. Circulating concentrations and molecular distribution of the acid-labile (α) subunit of the high molecular weight insulin-like growth factor-binding protein complex
10. Acid-labile subunit of human insulin-like growth factor-binding protein complex: Measurement, molecular, and clinical evaluation
11. Acromegaly
12. Epidemiology of acromegaly
13. Current treatment guidelines for acromegaly
14. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results
15. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
16. Characterization of 24-hour growth hormone secretion in acromegaly: Implications for diagnosis and therapy
17. Plasma insulin-like growth factor-1/somatomedin-C in acromegaly: Correlation with the degree of growth hormone hypersecretion
18. The ratio between serum concentrations of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients
19. Investigation protocol: Acromegaly and its investigation
20. Criteria for cure of acromegaly: A consensus statement
21. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review
22. Epidemiology of adult onset hypopituitarism in Goteborg, Sweden during 1956-1987
23. Clinical aspects of growth hormone deficiency in adults
24. Premature mortality due to cardiovascular disease in hypopituitarism
25. The assessment of growth hormone status in normal young adult males using a variety of provocative agents
26. Atropine blockade of growth hormone (GH)-releasing hormone-induced GH secretion in man is not exerted at pituitary concentration
27. Diagnosis of growth hormone deficiency in adults
28. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: Summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency
29. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone+arginine as provocative tests for the diagnosis of GH deficiency in adults
30. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults
31. Evaluation and application of a highly sensitive assay for serum growth hormone (GH) in the study of adult GH deficiency
32. The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: Hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency
33. Growth hormone (GH) insensitivity due to primary GH receptor deficiency
34. Lessons from the genetics of Laron syndrome
35. Phenotype: Genotype relationships in growth hormone insensitivity syndrome
36. The broad spectrum of inherited growth hormone insensitivity syndrome
37. Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism)
38. Absence of the plasma growth hormone-binding protein in Laron-type dwarfism
39. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome)
40. A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein
41. A dominant-negative mutation of the growth hormone receptor causes familial short stature
42. Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: Extended phenotypic study in a very large pedigree
43. A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein